NASDAQ:KERX - Keryx Biopharmaceuticals Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$3.36
+0 (0.00%)
Get New Keryx Biopharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KERX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KERX

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Keryx Biopharmaceuticals in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $3.36.

This chart shows the closing price for KERX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 contributing investment analysts is to n/a stock in Keryx Biopharmaceuticals. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/17/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/15/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/13/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/10/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/12/2018Raymond JamesDowngradeOutperform ➝ Market PerformHigh
11/9/2018HC WainwrightReiterated RatingBuy$9.00High
11/9/2018Maxim GroupReiterated RatingHoldHigh
10/2/2018HC WainwrightSet Price TargetBuy$9.00Medium
8/23/2018HC WainwrightSet Price TargetBuy$9.00Low
8/9/2018CitigroupLower Price TargetNeutral ➝ Neutral$4.75 ➝ $4.00Low
8/9/2018HC WainwrightReiterated RatingBuy$9.00High
6/28/2018Maxim GroupDowngradeBuy ➝ HoldHigh
6/28/2018HC WainwrightInitiated CoverageBuy$9.00High
6/25/2018Stifel NicolausReiterated RatingHold ➝ Hold$5.00Medium
5/10/2018Maxim GroupSet Price TargetBuy$9.00Low
2/8/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$7.00 ➝ $6.00Low
11/8/2017Stifel NicolausLower Price TargetHold$7.00 ➝ $5.00N/A
(Data available from 8/10/2017 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/13/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/10/2022

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Keryx Biopharmaceuticals logo
Keryx Biopharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on providing medicines for patients with kidney disease in the United States. It markets its lead product Auryxia (ferric citrate), an orally available, absorbable, iron-based medicine for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis, as well as for the treatment of iron deficiency anemia in adults with CKD not on dialysis. The company has strategic alliances with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of ferric citrate in Japan; and with Panion & BF Biotech, Inc. for the development and marketing of ferric citrate. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in Boston, Massachusetts.
Read More

Today's Range

Now: $3.36
Low: $2.97
High: $3.47

50 Day Range

MA: N/A

52 Week Range

Now: $3.36
Low: $2.47
High: $5.98

Volume

2,596,031 shs

Average Volume

1,688,993 shs

Market Capitalization

$344.00 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.35

Frequently Asked Questions

What sell-side analysts currently cover shares of Keryx Biopharmaceuticals?

The following sell-side analysts have issued research reports on Keryx Biopharmaceuticals in the last year:
View the latest analyst ratings for KERX.

What is the current price target for Keryx Biopharmaceuticals?

0 Wall Street analysts have set twelve-month price targets for Keryx Biopharmaceuticals in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Keryx Biopharmaceuticals in the next year.
View the latest price targets for KERX.

What is the current consensus analyst rating for Keryx Biopharmaceuticals?

Keryx Biopharmaceuticals currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for KERX.

What other companies compete with Keryx Biopharmaceuticals?

How do I contact Keryx Biopharmaceuticals' investor relations team?

Keryx Biopharmaceuticals' physical mailing address is ONE MARINA PARK DR., BOSTON MA, 02210. The biopharmaceutical company's listed phone number is 617-466-3500 and its investor relations email address is [email protected] The official website for Keryx Biopharmaceuticals is www.keryx.com. Learn More about contacing Keryx Biopharmaceuticals investor relations.